AVDL News & Events

Monopar Therapeutics (MNPR) announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application to the U.S. Food and Drug Administration in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease. She most recently served as COO of Avadel Pharmaceuticals (AVDL).

Avadel Pharmaceuticals (AVDL) announced that the Irish High Court has sanctioned, without modification, the scheme of arrangement between Avadel and its shareholders under Chapter 1 of Part 9 of the Irish Companies Act 2014 pursuant to which Alkermes (ALKS) will acquire the entire issued and to be issued ordinary share capital of Avadel. Completion of the proposed transaction remains subject to the delivery to the Registrar of Companies of a copy of the Court Order sanctioning the Scheme. Assuming that a copy of the Court Order is processed and made available to Avadel by no later than February 11, the Court Order is expected to be delivered to the Registrar of Companies on February 12 and, accordingly, the Scheme is expected to take effect on February 12. Accordingly, February 11 is expected to be the last date on which trading of Avadel Shares on Nasdaq will occur. It is expected that Avadel will request Nasdaq halt trading of the Avadel Shares effective as of 8.00 p.m. on February 11.

Avadel Pharmaceuticals (AVDL) announced that, in relation to the previously announced offer for the company by Alkermes (ALKS), pursuant to which Alkermes will acquire the entire issued and to be issued ordinary share capital of the company, the resolutions required to approve the scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 were passed by the requisite majorities at the scheme meeting of shareholders and the related extraordinary general meeting of shareholders held earlier.